5 patents
Utility
Crystalline Forms of a Cannabinoid Receptor Type 1 (CB1) Modulator and Methods of Use and Preparation Thereof
11 Jan 24
Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of the CB1 receptor.
Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER
Filed: 20 Sep 23
Utility
Formulations and Methods for Treating Acute Cannabinoid Overdose
4 Jan 24
Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose or suspected of a drug overdose.
Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER
Filed: 17 Nov 21
Utility
Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof
24 Oct 23
Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of the CB1 receptor.
Joseph Fenton Lawler, Daniel Pawel Schneeberger
Filed: 10 Oct 22
Utility
Crystalline Forms of a Cannabinoid Receptor Type 1 (CB1) Modulator and Methods of Use and Preparation Thereof
4 May 23
Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of the CB1 receptor.
Joseph Fenton LAWLER, Daniel Pawel SCHNEEBERGER
Filed: 10 Oct 22
Utility
Formulations and methods for treating acute cannabinoid overdose
12 Oct 21
Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose or suspected of a drug overdose.
Joseph Fenton Lawler, Daniel Pawel Schneeberger
Filed: 20 Nov 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first